Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer
Margherita Ambrosini(Assistance Publique – Hôpitaux de Paris), Filippo Pietrantonio(Fondazione IRCCS Istituto Nazionale dei Tumori), Oliver Artz(Memorial Sloan Kettering Cancer Center), Veronica Conca(University of Pisa), Lena Weiss(LMU Klinikum), Priya Jayachandran(Los Angeles Medical Center), Imane El Dika(Memorial Sloan Kettering Cancer Center), Brennan Decker(Boston Foundation), Maaz Khan Afghan(University of Iowa), Benoı̂t Rousseau(Memorial Sloan Kettering Cancer Center), Giacomo Mazzoli(Fondazione IRCCS Istituto Nazionale dei Tumori), Anna M. Varghese(Memorial Sloan Kettering Cancer Center), Albert Grinshpun(Hebrew University of Jerusalem), Elena Élez(Vall d'Hebron Hospital Universitari), Richard L. Schilsky(American Society of Clinical Oncology), Andrea Cercek(Memorial Sloan Kettering Cancer Center), Leonard B. Saltz(Memorial Sloan Kettering Cancer Center), Rona Yaeger(Memorial Sloan Kettering Cancer Center), Paolo Manca(Fondazione IRCCS Istituto Nazionale dei Tumori), Areeb Lutfi(University of Iowa), Romain Cohen(Sorbonne Université), Sara Lonardi(Istituto Oncologico Veneto), C. Benedikt Westphalen(LMU Klinikum), G. Maddalena(Istituto Oncologico Veneto), Oded Margalit(Tel Aviv University), Marwan Fakih(City of Hope), Alexa B. Schrock(GlobalFoundries (United States)), Neil H. Segal(Kettering University), Aurélien Marabelle(Institut Gustave Roussy), Giovanni Randon(Fondazione IRCCS Istituto Nazionale dei Tumori), Geoffrey Y. Ku(Memorial Sloan Kettering Cancer Center), Pashtoon Murtaza Kasi(Cornell University), Einat Shacham‐Shmueli(Sheba Medical Center), Thierry André(Inserm), Chiara Cremolini(University of Pisa), Zoe Goldberg(Memorial Sloan Kettering Cancer Center), Maliha Nusrat(Memorial Sloan Kettering Cancer Center), R. Intini(Istituto Oncologico Veneto), Michael J. Overman(The University of Texas MD Anderson Cancer Center)
Cited by 73
Related Papers
Colorectal cancer
|The Lancet|2019|5k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Colorectal cancer statistics, 2023
|CA A Cancer Journal for Clinicians|2023|3.8k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k